1. Home
  2. BLTE vs KLIC Comparison

BLTE vs KLIC Comparison

Compare BLTE & KLIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$154.26

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Logo Kulicke and Soffa Industries Inc.

KLIC

Kulicke and Soffa Industries Inc.

HOLD

Current Price

$103.81

Market Cap

7.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLTE
KLIC
Founded
2018
1951
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
7.0B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
BLTE
KLIC
Price
$154.26
$103.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
3
Target Price
$198.00
$54.67
AVG Volume (30 Days)
197.8K
1.4M
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
0.98%
EPS Growth
N/A
100.32
EPS
N/A
0.98
Revenue
N/A
$654,081,000.00
Revenue This Year
N/A
$45.81
Revenue Next Year
$492.11
$11.35
P/E Ratio
N/A
$106.34
Revenue Growth
N/A
N/A
52 Week Low
$59.12
$31.33
52 Week High
$200.00
$135.80

Technical Indicators

Market Signals
Indicator
BLTE
KLIC
Relative Strength Index (RSI) 54.28 40.47
Support Level $148.00 $95.38
Resistance Level $161.28 $108.89
Average True Range (ATR) 7.57 9.11
MACD 1.14 -2.96
Stochastic Oscillator 74.33 8.57

Price Performance

Historical Comparison
BLTE
KLIC

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

About KLIC Kulicke and Soffa Industries Inc.

Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.

Share on Social Networks: